The content on this site is intended for healthcare professionals only
Dr Javier Cortés speaks to ecancer about the results of the randomised phase 3 DESTINY-Breast03 study. Initially, he explains the rationale and design of the study.
This study investigated trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer. He says that T-DXd demonstrated a highly statistically significant and clinically meaningful improvement in PFS vs T-DM1 in patients previously treated with trastuzumab and taxane for HER2+ mBC.
These data confirm that T-DXd is tolerable with manageable toxicity and a significant improvement in ILD profile vs studies performed in more heavily pretreated patients.
Dr Cortés concludes by discussing the impact these results can have on the future treatment of breast cancer.
Read more about the study here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC
Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
SABCS 2023: Highlights
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
